A Phase I Double-Blind, Randomised, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of UE2343 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 04 May 2017
At a glance
- Drugs UE 2343 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Actinogen Medical
- 28 Apr 2017 Results from this trial have been published in the British Journal of Pharmacology in February 2017, according to an Actinogen Medical media release.
- 25 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 29 Sep 2015 Results were published in an Actinogen media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History